Esperion Therapeutics, Inc.
ESPR
$3.78
$0.123.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 303.80M | 268.13M | 259.57M | 332.31M | 295.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 303.80M | 268.13M | 259.57M | 332.31M | 295.45M |
| Cost of Revenue | 171.90M | 144.17M | 135.46M | 114.84M | 107.43M |
| Gross Profit | 131.90M | 123.96M | 124.12M | 217.48M | 188.03M |
| SG&A Expenses | 161.28M | 159.41M | 164.08M | 163.07M | 171.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 333.18M | 303.57M | 299.54M | 277.91M | 279.00M |
| Operating Income | -29.38M | -35.45M | -39.96M | 54.40M | 16.46M |
| Income Before Tax | -105.83M | -104.02M | -153.22M | -51.75M | -86.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.83 | -104.02 | -153.22 | -51.75 | -86.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.83M | -104.02M | -153.22M | -51.75M | -86.77M |
| EBIT | -29.38M | -35.45M | -39.96M | 54.40M | 16.46M |
| EBITDA | -29.27M | -35.34M | -39.88M | 54.50M | 16.53M |
| EPS Basic | -0.54 | -0.53 | -0.79 | -0.23 | -0.62 |
| Normalized Basic EPS | -0.33 | -0.33 | -0.32 | 0.04 | -0.21 |
| EPS Diluted | -0.54 | -0.53 | -0.80 | -0.25 | -0.65 |
| Normalized Diluted EPS | -0.33 | -0.33 | -0.32 | 0.01 | -0.24 |
| Average Basic Shares Outstanding | 789.98M | 784.17M | 775.42M | 748.55M | 665.39M |
| Average Diluted Shares Outstanding | 789.98M | 784.17M | 775.42M | 768.93M | 685.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |